Vertex Pharmaceuticals (VRTX) Change in Account Payables (2009 - 2026)

Vertex Pharmaceuticals' Change in Account Payables history runs 18 years deep, the most recent figure standing at $35.6 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 35.88% year-over-year to $35.6 million; the TTM figure through Mar 2026 stood at $46.2 million (down 38.89% YoY), while the FY2025 annual figure was $36.8 million, down 25.66% from the prior year.
• Change in Account Payables for Q1 2026 stood at $35.6 million, down from $38.3 million in the prior quarter.
• The five-year high for Change in Account Payables was $159.9 million in Q4 2022, with the low at -$69.9 million in Q3 2022.
• The 5-year median for Change in Account Payables is $9.2 million (2023), against an average of $17.1 million.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables tumbled 3139.13% in 2022, then surged 26100.0% in 2025.
• Vertex Pharmaceuticals' Change in Account Payables stood at $159.9 million in 2022, then tumbled by 119.89% to -$31.8 million in 2023, then jumped by 126.42% to $8.4 million in 2024, then soared by 355.95% to $38.3 million in 2025, then retreated by 7.05% to $35.6 million in 2026.
• Business Quant data shows VRTX's Change in Account Payables at $35.6 million in Q1 2026, $38.3 million in Q4 2025, and -$35.3 million in Q3 2025.